<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="82898">
  <stage>Registered</stage>
  <submitdate>12/06/2008</submitdate>
  <approvaldate>8/08/2008</approvaldate>
  <actrnumber>ACTRN12608000398303</actrnumber>
  <trial_identification>
    <studytitle>Wellness Study</studytitle>
    <scientifictitle>Efficacy of low dose escitalopram v's placebo in the amelioration of anxiety and fatigue in patients who are unwell or suffer chronic illness</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Chronic illness - patients who are generally unwell for an extended period.</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Conditions of unknown or disputed aetiology (such as chronic fatigue syndrome/myalgic encephalomyelitis)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>0.05mg escitalopram oxalate in a lactose base in an opaque capsule. 1 capsule taken daily via oral route for a period of 6 weeks.</interventions>
    <comparator>Lactose in an opaque capsule. 1 capsule taken daily via oral route for a period of 6 weeks.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Reduction in fatigue assessed by Fatigue Assessment Scale.</outcome>
      <timepoint>Screening and 6 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Reduction in anxiety assessed by Spielberger Questionnaire and Hospital Anxiety and Depression (HAD) Scale.</outcome>
      <timepoint>Baseline, screening and 6 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Increase in effort tolerance as assessed by the Medical Research Council (MRC) Dyspnoea Scale.</outcome>
      <timepoint>Baseline, screening and 6 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Chronic illness - patients who are generally unwell for an extended period.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>85</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with Malignancy or taking any prescribed antidepressant and/or pyschotrophic medication will be excluded from the trial.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation schedule held by separate party.</concealment>
    <sequence>Simple randomisation table created by a computer based statistical program</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/01/2008</anticipatedstartdate>
    <actualstartdate>20/07/2007</actualstartdate>
    <anticipatedenddate />
    <actualenddate>13/06/2011</actualenddate>
    <samplesize>50</samplesize>
    <actualsamplesize>42</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <postcode>6008</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>Mood Research Foundation (WA)</primarysponsorname>
    <primarysponsoraddress>Suite 4 336 Churchill Ave
SUBIACO  WA  6008</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Mood Research Foundation (WA)</fundingname>
      <fundingaddress>Suite 4 336 Churchill Ave
SUBIACO  WA  6008</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Hans Stampfer</othercollaboratorname>
      <othercollaboratoraddress>Sir Charles Gairdner Hospital
Hospital Ave
NEDLANDS  WA  6009</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The Wellness Study will evaluate 6 weeks of very low dose Escitalopram (50 micrograms) compared to placebo on fatigue, anxiety and depression in chronic medical illness. Following a 3 week baseline run in-phase, participants will be randomised 'double blind' to the active or placebo treatment, incorporating 4 study centre visits in all. Associated clinical benefits may include improvements in sleep, weight reduction, heart rate and blood pressure. Although serotonin re-uptake inhibitors have never previously been studied at such a low dose, clinical results to date appear encouraging.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St John of God Hospital Subiaco Campus</ethicname>
      <ethicaddress>St John of God House
175 Cambridge St
SUBIACO  WA  6008</ethicaddress>
      <ethicapprovaldate>7/12/2006</ethicapprovaldate>
      <hrec>133</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St John of God Hospital Subiaco Campus</ethicname>
      <ethicaddress>St John of God House
175 Cambridge St
SUBIACO  WA  6008</ethicaddress>
      <ethicapprovaldate>7/12/2006</ethicapprovaldate>
      <hrec>133</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Dr Simon Dimmitt</name>
      <address>Suite 304
25 McCourt St
SUBIACO  WA  6008</address>
      <phone>08 9382 9580</phone>
      <fax />
      <email>sdimmitt@bigpond.com</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Dr Simon Dimmitt</name>
      <address>Suite 304
25 McCourt St
SUBIACO  WA  6008</address>
      <phone>08 9382 9580</phone>
      <fax />
      <email>sdimmitt@bigpond.com</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Alicia Sinclair</name>
      <address>Suite 304
25 McCourt St
SUBIACO  WA  6008</address>
      <phone />
      <fax />
      <email>alicia@achf.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>Simon Dimmitt</name>
      <address>Suite 304 25 McCourt St 
SUBIACO  WA  6008</address>
      <phone>+61 8 63809585</phone>
      <fax />
      <email>alicia@achf.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>